S. Couture, Liktor-Busa, Villar Martinez, Gongora-Rivera, Hernandez-Sanchez, Pte. Cons, Mexico Col. Obispado, Razeghi Jahromi
ABHD6 partially reversed medication overuse headache induced allodynia induced by sumatriptan. Background : The pathophysiology of headache disorders such as medication overuse headache (MOH) is poorly understood, making treatment difficult. However, recent evidence has implicated the involvement of endocannabinoid deficiency, specifically in decreased levels of 2-AG within periaqueductal gray (PAG), in multiple models of headache pain. Our previous research has shown that blockade of 2-AG degradation using a selective ABHD6 inhibitor, KT-182, both prevented and reversed periorbital allodynia in a cortical spreading depression (CSD) headache model. Given our observations that MOH also reduced PAG levels of 2-AG, this study aimed to evaluate the efficacy of inhibiting ABHD6 for MOH headache like pain behaviors
{"title":"American Headache Society 66th Annual Scientific Meeting June 13–16, 2024 San Diego, California","authors":"S. Couture, Liktor-Busa, Villar Martinez, Gongora-Rivera, Hernandez-Sanchez, Pte. Cons, Mexico Col. Obispado, Razeghi Jahromi","doi":"10.1111/head.14771","DOIUrl":"https://doi.org/10.1111/head.14771","url":null,"abstract":"ABHD6 partially reversed medication overuse headache induced allodynia induced by sumatriptan. Background : The pathophysiology of headache disorders such as medication overuse headache (MOH) is poorly understood, making treatment difficult. However, recent evidence has implicated the involvement of endocannabinoid deficiency, specifically in decreased levels of 2-AG within periaqueductal gray (PAG), in multiple models of headache pain. Our previous research has shown that blockade of 2-AG degradation using a selective ABHD6 inhibitor, KT-182, both prevented and reversed periorbital allodynia in a cortical spreading depression (CSD) headache model. Given our observations that MOH also reduced PAG levels of 2-AG, this study aimed to evaluate the efficacy of inhibiting ABHD6 for MOH headache like pain behaviors","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"79 5‐6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141414359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in patients aged 6 to 11 years.
评价唑米曲坦鼻喷雾剂(ZNS)治疗6 ~ 11岁急性偏头痛患者的疗效和安全性。
{"title":"A multicenter, randomized, double‐blind, placebo‐controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open‐label extension","authors":"M. Yonker, J. McVige, L. Zeitlin, H. Visser","doi":"10.1111/head.14391","DOIUrl":"https://doi.org/10.1111/head.14391","url":null,"abstract":"To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in patients aged 6 to 11 years.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"108 1","pages":"1207 - 1217"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74647987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer I. Stern, Chia-Chun Chiang, N. Kissoon, C. Robertson
To provide an overview of the current available literature on peripheral nerve blocks for the management of migraine and other headache disorders in adults.
概述目前关于周围神经阻滞治疗成人偏头痛和其他头痛疾病的文献。
{"title":"Narrative review of peripheral nerve blocks for the management of headache","authors":"Jennifer I. Stern, Chia-Chun Chiang, N. Kissoon, C. Robertson","doi":"10.1111/head.14385","DOIUrl":"https://doi.org/10.1111/head.14385","url":null,"abstract":"To provide an overview of the current available literature on peripheral nerve blocks for the management of migraine and other headache disorders in adults.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"56 1","pages":"1077 - 1092"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90906462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
might be withheld from them because these medications are not approved for episodic migraine (such as botulinumtoxin and the same for calcitonin gene- related peptide antibodies in some coun -tries). Changing ICHD criteria might seem like a viable solution for this problem. When looking at the consequences for the use of already Food and Drug Administration– approved treatments one, however, must be very careful. If a clinical trial has applied the current ICHD criteria for episodic and CM, a benefit for the group of CM patients means that there is a benefit for patients with 15 or more headache days per month and not for those with less, regardless of what we call the subtype of migraine. 19 Should we choose to change the nomenclature and call migraine with eight or more headache days chronic, that still does not alter the sci entific evidence that the clinical efficacy has been established in patients with ≥15 headache days. Indication for a specific medica tion can only be broadened if new evidence may suggest efficacy in another subgroup of patients. For example, a recent open- label study suggests probable efficacy of onabotulinumtoxinA in pa tients with HFEM, 20 which itself needs to be confirmed in a proper randomized controlled trial. When treating patients with severe pain conditions one is often faced with a lot of despair and those in despair will clutch at a straw. As responsible physicians, our ac tions must be evidence based. Consequently, we must not subject patients to treatments that have not been shown to be effective in their condition regardless of what the condition is called. We do appreciate the call to broaden the indication of certain medi cations to a higher number of patients. The solution is however not to simply include HFEM into CM, but to do proper studies in HFEM patients with medications that have proven efficacy in CM.
{"title":"The 15‐day threshold in the definition of chronic migraine is reasonable and sufficient—Five reasons for not changing the ICHD‐3 definition","authors":"Laura Fischer-Schulte, A. May","doi":"10.1111/head.14383","DOIUrl":"https://doi.org/10.1111/head.14383","url":null,"abstract":"might be withheld from them because these medications are not approved for episodic migraine (such as botulinumtoxin and the same for calcitonin gene- related peptide antibodies in some coun -tries). Changing ICHD criteria might seem like a viable solution for this problem. When looking at the consequences for the use of already Food and Drug Administration– approved treatments one, however, must be very careful. If a clinical trial has applied the current ICHD criteria for episodic and CM, a benefit for the group of CM patients means that there is a benefit for patients with 15 or more headache days per month and not for those with less, regardless of what we call the subtype of migraine. 19 Should we choose to change the nomenclature and call migraine with eight or more headache days chronic, that still does not alter the sci entific evidence that the clinical efficacy has been established in patients with ≥15 headache days. Indication for a specific medica tion can only be broadened if new evidence may suggest efficacy in another subgroup of patients. For example, a recent open- label study suggests probable efficacy of onabotulinumtoxinA in pa tients with HFEM, 20 which itself needs to be confirmed in a proper randomized controlled trial. When treating patients with severe pain conditions one is often faced with a lot of despair and those in despair will clutch at a straw. As responsible physicians, our ac tions must be evidence based. Consequently, we must not subject patients to treatments that have not been shown to be effective in their condition regardless of what the condition is called. We do appreciate the call to broaden the indication of certain medi cations to a higher number of patients. The solution is however not to simply include HFEM into CM, but to do proper studies in HFEM patients with medications that have proven efficacy in CM.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85347726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chia-Chun Chiang, Nikita Chhabra, C. Chao, Han Wang, N. Zhang, Elisabeth Lim, Abraham Baez-Suarez, Z. Attia, T. Schwedt, D. Dodick, F. M. Cutrer, P. Friedman, P. Noseworthy
To compare the artificial intelligence‐enabled electrocardiogram (AI‐ECG) atrial fibrillation (AF) prediction model output in patients with migraine with aura (MwA) and migraine without aura (MwoA).
{"title":"Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men","authors":"Chia-Chun Chiang, Nikita Chhabra, C. Chao, Han Wang, N. Zhang, Elisabeth Lim, Abraham Baez-Suarez, Z. Attia, T. Schwedt, D. Dodick, F. M. Cutrer, P. Friedman, P. Noseworthy","doi":"10.1111/head.14339","DOIUrl":"https://doi.org/10.1111/head.14339","url":null,"abstract":"To compare the artificial intelligence‐enabled electrocardiogram (AI‐ECG) atrial fibrillation (AF) prediction model output in patients with migraine with aura (MwA) and migraine without aura (MwoA).","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"45 1","pages":"939 - 951"},"PeriodicalIF":0.0,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82228732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We sought to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage, and to explore specifics of the medication prescribed, dosage, and route of administration.
{"title":"Triptan medication use among patients with migraine with contraindications in the US","authors":"Adriana Pero, A. Pace, M. Dhamoon","doi":"10.1111/head.14327","DOIUrl":"https://doi.org/10.1111/head.14327","url":null,"abstract":"We sought to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage, and to explore specifics of the medication prescribed, dosage, and route of administration.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"10 1","pages":"883 - 889"},"PeriodicalIF":0.0,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75191017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate whether web searching for headache disorders presents some circannual rhythm.
探讨头痛疾病的网络搜索是否有一定的周期性。
{"title":"Seasonal changes of internet searching suggest circannual rhythmicity of primary headache disorders","authors":"Jakub Radziwon, P. Waszak","doi":"10.1111/head.14329","DOIUrl":"https://doi.org/10.1111/head.14329","url":null,"abstract":"To investigate whether web searching for headache disorders presents some circannual rhythm.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":" 4","pages":"811 - 817"},"PeriodicalIF":0.0,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91415183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erdi Şahin, Z. Karaaslan, E. Şanlı, Özlem Tımırcı Kahraman, C. Ulusoy, Elif Kocasoy Orhan, E. Ekizoğlu, C. Küçükali, E. Tüzün, B. Baykan
The involvement of inflammation in the pathophysiology of cluster headache (CH) has been suggested, with a role implied for interleukin (IL)‐1β. We aimed to measure peripheral blood expression levels of IL‐1β–inducing systems, the inflammasome complex, and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) signaling, and investigate their values as putative biomarkers in CH.
{"title":"Reduced expression of inflammasome complex components in cluster headache","authors":"Erdi Şahin, Z. Karaaslan, E. Şanlı, Özlem Tımırcı Kahraman, C. Ulusoy, Elif Kocasoy Orhan, E. Ekizoğlu, C. Küçükali, E. Tüzün, B. Baykan","doi":"10.1111/head.14334","DOIUrl":"https://doi.org/10.1111/head.14334","url":null,"abstract":"The involvement of inflammation in the pathophysiology of cluster headache (CH) has been suggested, with a role implied for interleukin (IL)‐1β. We aimed to measure peripheral blood expression levels of IL‐1β–inducing systems, the inflammasome complex, and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) signaling, and investigate their values as putative biomarkers in CH.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"8 1","pages":"967 - 976"},"PeriodicalIF":0.0,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88100921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Silva, F. R. Ortiz, L. M. Maracci, Gabriela B P Silva, R. S. Salbego, G. Liedke, M. Marquezan
To evaluate the association between headache, myofascial temporomandibular disorder (TMD), and awake bruxism (AB).
评估头痛、颞下颌肌筋膜障碍(TMD)和清醒磨牙症(AB)之间的关系。
{"title":"Association among headache, temporomandibular disorder, and awake bruxism: A cross‐sectional study","authors":"T. Silva, F. R. Ortiz, L. M. Maracci, Gabriela B P Silva, R. S. Salbego, G. Liedke, M. Marquezan","doi":"10.1111/head.14322","DOIUrl":"https://doi.org/10.1111/head.14322","url":null,"abstract":"To evaluate the association between headache, myofascial temporomandibular disorder (TMD), and awake bruxism (AB).","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"8 1","pages":"748 - 754"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77780952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Starling, M. Cortez, N. Jarvis, Nan Zhang, F. Porreca, C. Chong, T. Schwedt
The purpose of this study was to characterize cutaneous heat and light‐induced pain thresholds in people with post‐traumatic headache (PTH) compared with healthy controls (HCs).
本研究的目的是比较创伤后头痛(PTH)患者与健康对照组(hc)的皮肤热和光诱导疼痛阈值。
{"title":"Cutaneous heat and light‐induced pain thresholds in post‐traumatic headache attributed to mild traumatic brain injury","authors":"A. Starling, M. Cortez, N. Jarvis, Nan Zhang, F. Porreca, C. Chong, T. Schwedt","doi":"10.1111/head.14318","DOIUrl":"https://doi.org/10.1111/head.14318","url":null,"abstract":"The purpose of this study was to characterize cutaneous heat and light‐induced pain thresholds in people with post‐traumatic headache (PTH) compared with healthy controls (HCs).","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"5 1","pages":"726 - 736"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76403675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：